[Calcium blockers in the therapy of vertebrobasilar insufficiency. Results of animal experiments and clinical studies].

Abstract

Vertebrobasilar insufficiency (VBI) is a clinical syndrome which includes different transient brain stem symptoms. In addition to anamnesis and clinical study electronystagmography (ENG) is regarded as the most important method for testing the labyrinthine and brain stem system. Typical findings, not only in patients with VBI, but also in animal experiments (occlusion of one vertebral artery) are an increase in nystagmus frequency and decrease in nystagmus amplitude. The present study concerns two calcium antagonists: flunarizine and nimodipine. During tests on patients the caloric and the rotatory nystagmus and during animal experiments the rotatory nystagmus was investigated. Patient tests as well as animal experiments showed, that flunarizine and nimodipine have a depressant influence on the pathologically increased nystagmus frequency. With both substances there was also a trend to normalization of nystagmus amplitude as well as an improvement of clinical symptoms.

• Authors: B Hofferberth
• Journal: Fortschritte der Medizin (Fortschr Med) Vol. 102 Issue 27-28 Pg. 725-8 (Jul 26 1984) ISSN: 0015-8178 [Print] Germany
• Vernacular Title: Kalzium-Blocker in der Therapie der vertebrobasilären Insuffizienz. Ergebnisse tierexperimenteller und klinischer Studies.
• PMID: 6383990 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, English Abstract, Journal Article)

Chemical References

• Calcium Channel Blockers
• Nicotinic Acids
• Piperazines
• Cinnarizine
• Nimodipine
• Sulpiride
• Flunarizine
• Pentoxifylline

Topics

• Animals
• Calcium Channel Blockers (therapeutic use)
• Cerebrovascular Circulation (drug effects)
• Cinnarizine (analogs & derivatives, therapeutic use)
• Clinical Trials as Topic
• Dogs
• Double-Blind Method
• Flunarizine
• Humans
• Nicotinic Acids (therapeutic use)
• Nimodipine
• Pentoxifylline (therapeutic use)
• Piperazines (therapeutic use)
• Sulpiride (therapeutic use)
• Vertebrobasilar Insufficiency (drug therapy)
• Vertigo (drug therapy)